Newsroom | 4331 results

SAN DIEGO--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS® drug discovery platform, announced today it has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to further advance its data-driven drug discovery capabilities. Omics technologies enable comprehensive characterization of cellular systems. This means phenot...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that it will present at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California. Secretome Therapeutics’ presentation is scheduled for Thursday, January 15, 2026, from 9:00 AM to 9:25 AM (PT). During the presentation, the company w...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders’ and investors’ holiday schedules — the call will now take place on Wednesday, January 7,...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units (“RSUs”) to a new employee under the Precision BioSciences, Inc. 2021 Employment In...

WILMINGTON, Del.--(BUSINESS WIRE)--Predicting how a person’s heart will respond to a new medicine remains one of the most persistent blind spots in drug development. Even with decades of scientific progress, cardiotoxicity can still emerge unexpectedly, carrying enormous financial costs and, more importantly, real human consequences. Today, that challenge is being met with a bold new vision. InSilicoTrials is proud to lead with The Jackson Laboratory (JAX) under the leadership of Dr. Matt Mahon...

シアトル--(BUSINESS WIRE)--（ビジネスワイヤ） -- スケーラブルで利用しやすい単一細胞シーケンシングソリューションの主要プロバイダーであるパース・バイオサイエンシズ（Parse Biosciences）は、Codebreaker Labsとの協業を発表しました。本協業では、数千の遺伝子バリアントを並列に評価し、その影響を単一細胞解像度で測定できる画期的なプラットフォームを開発・検証します。Codebreakerの合成生物学プラットフォームおよびバリアントエンジニアリングの能力を、パース・バイオサイエンシズのEvercode™技術が持つ拡張性や導入の容易さと組み合わせることで、AI開発者、創薬チーム、そして臨床研究者の間で需要が高まりつつある因果データの創出を目指しています。 現在のゲノミクス研究は、観察データ（大規模集団の中で確認されるバリアント）に大きく依存しています。しかし、一部の個人または限られた家系内でのみ見られることが多い希少バリアントやプライベートバリアントは、統計的に意味のある結論を導くのに十分な保有者数が存在しないため、この方法では解析がほぼ不可能...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, der führende Anbieter skalierbarer, zugänglicher Lösungen für die Einzelzell-Sequenzierung, gab heute eine Zusammenarbeit mit Codebreaker Labs bekannt, um eine bahnbrechende Plattform, die Tausende genetischer Varianten parallel testen und deren Auswirkungen mit Einzelzellauflösung messen kann, zu entwickeln und zu validieren. Durch die Kombination von Codebreakers Plattform für synthetische Biologie sowie dessen Fähigkeiten im Variant Engineering mi...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, principal fournisseur de solutions de séquençage unicellulaire évolutives et accessibles, annonce aujourd'hui une collaboration avec Codebreaker Labs afin de développer et valider une plateforme innovante, capable de tester des milliers de variantes génétiques en parallèle et de mesurer leurs effets à l'échelle de la cellule unique. En associant la plateforme de biologie synthétique et les capacités d'ingénierie des variantes de Codebreaker à l'évolu...

SEATTLE--(BUSINESS WIRE)--A Parse Biosciences, líder no fornecimento de soluções escaláveis e acessíveis de sequenciamento de células individuais, anunciou hoje uma colaboração com a Codebreaker Labs para desenvolver e validar uma plataforma inovadora capaz de testar milhares de variantes genéticas em paralelo e medir seus efeitos com resolução de célula única. Combinando a plataforma de biologia sintética e os recursos de engenharia de variantes da Codebreaker com a escala e acessibilidade da...